Inventiva Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel and differentiated oral small molecule therapies for patients with significant unmet medical needs. With a focus on fibrosis, lysosomal storage disorders, and oncology, Inventiva aims to provide effective treatment options for patients suffering from these diseases. They have built a strong pipeline of potential therapies, supported by an extensive library of proprietary molecules and state-of-the-art research and development facilities.

Their lead product candidate, lanifibranor, is an anti-fibrotic treatment targeting metabolic, inflammatory, and fibrotic processes. In addition, they are developing a second clinical program with odiparcil for the treatment of mucopolysaccharidosis type VI (MPS) and investigating its potential for treating other MPS types. With a highly qualified team and a commitment to innovation, Inventiva strives to be a leader in developing drugs that interact with nuclear receptors, transcription factors, and epigenetic modulators